Search for a trial

*A Phase 2b Multicentre, Randomised, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of PQ912 in Subjects with Mild Cognitive Impairment and Mild Dementia due to Alzheimer*s Disease.*

Primary objectives:Safety for Dose Selection• To assess the safety and tolerability of PQ912Efficacy • To evaluate the efficacy of PQ912 on working memory and attentionSecondary Objectives:Safety• To assess the safety and tolerability of long-term…

Approaches to advance care planning for persons with dementia and their family caregivers: a cluster-randomized controlled trial.

We aim to assess the effects of two approaches of ACP (detailed advance treatment orders versus global goal setting and coping based) on wellbeing of persons with dementia. In addition, we will assess effects on decisional conflict, self-efficacy to…

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease and APOE4/4 Genotype

ALZ-801 is an oral agent that is being developed as a potential disease modifying treatment for AD. This 78-week Phase 3 study will focus on Early AD subjects who carry the APOE4/4 genotype, and is designed according to current regulatory guidance…

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease

This study has been transitioned to CTIS with ID 2024-511770-76-00 check the CTIS register for the current data. Primary* To assess safety and tolerability of IBC-Ab002 following single and multiple ascending doses in persons with early ADSecondary…

Dementia risk reduction in the general practice: a tailored approach

To test the feasibility of supplying a tailored, digital health app, designed to increase insight in how to reduce one*s dementia risk, in the general practice. Secondly, we aim to explore the usability of experience-sampling method (ESM) technology…

A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment (MCI)

The aim of this study is to examine whether roflumilast improves cognition in clinical patients with MCI or mild dementia.

A Phase 2b/3, Double-Blind, Randomised, Placebo-Controlled 48-week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer*s Disease (AD).

Primary Objectives:* Change from baseline to week 48 in cognition according to the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog) compared to placebo.* Changes from baseline to week 48 in ability to perform daily activities according to the…

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)

Primary objective:• Evaluate the safety and tolerability of WVE-004 in patients with ALS or FTD with a documented mutation in the C9orf72 gene.Secondary objectives:• Characterize the pharmacokinetics (PK) of WVE-004 in plasma.• Characterize…

A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer*s type.

The primary objective is to:* Evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo for thetreatment of agitation in patients with dementia of the Alzheimer*s typeThe secondary objectives are to:* Evaluate the effects of AVP…

A randomized, double-blind, placebo-controlled, parallel-group, phase 2 study to evaluate the safety and efficacy of CT1812 in subjects with mild to moderate Alzheimer's disease

The purpose of this study is to evaluate the safety and efficacy of two doses of the study drug CT1812 per day for six months in subjects with mild to moderate Alzheimer's disease. CT1812 will be compared with a placebo. A placebo is a product…

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients

Primary objective:The main objective of the present trial are:• to evaluate the effect of TW001 on oxidative stress biomarkers• to evaluate the safety of TW001 in patients with Alzheimer*s DiseaseSecondary objective:The secondary objective of the…

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE AND MULTIPLE ASCENDING DOSES OF THN391 IN HEALTHY SUBJECTS

This study has been transitioned to CTIS with ID 2024-517955-10-00 check the CTIS register for the current data. In this study we will investigate how safe the new compound THN391 is and how well it is tolerated when it is used by healthy subjects.…

Trial NL77388.056.21

Publication withdrawn by sponsor

A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY
STUDY OF MTAU9937A IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER*S DISEASE

This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of MTAU9937A in patients with prodromal or mild Alzheimer*s disease (AD), ages 50*80, who are amyloid positive by cerebrospinal fluid (CSF) or amyloid positron…

A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects with Mild Alzheimer*s Disease.

The primary objective is to evaluate the effects of administration of neflamapimod (VX-745) for 24-weeks on immediate and delayed recall aspects of episodic memory, as assessed by the Hopkins Verbal Learning Test * Revised (HVLT-R) in subjects with…

Improvement of engagement in physical activities and quality of life in dementia: a study into the (cost-)effectiveness of exergaming

We want to study the effects and cost-effectivity with an randomised controlled trial in which we compare participants with dementia (and their informal caregiver) in daycentres which offer exergaming with participants in daycentres that offer…

Individual music therapy and wellbeing in nursing home residents with dementia
A study protocol of a randomized controlled trial

The present study aims to address the limitations of earlier research, by employing a large sample size, and investigating the possibility that music therapy has an effect on wellbeing of people with dementia when using blinded outcome assessments…

The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment

We aim to assess whether aerobic exercise leads to increased cerebral perfusion in patients with vascular cognitive impairment.

Differential physiological and cognitive effects of the COACH method in healthy elderly APOEe4 carriers and non-carriers

Part 1: Main objective: Investigate the relation between level of physical (in)activity and cognition in healthy elderly and to examine the possible moderating effects of (Apolipoprotein E e4) APOEe4 status and IGF-1 and BDNF levels and blood…

A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of the Oral P38 Alpha Kinase Inhibitor Neflamapimod in Dementia with Lewy Bodies (DLB)

The primary objective is to evaluate the effect of neflamapimod on cognitive function as assessed in a study-specific Neuropsychological Test Battery (NTB) comprised of:*Cogstate Detection test (DET)*Cogstate Identification test (IDN)*Cogstate One…